#United States #Ann Arbor #Genomenon #Cancer Knowledgebase #iFlow

Advancing Cancer Genomics with Intelliseq and Genomenon

In a significant move to improve cancer genomics, Intelliseq, a prominent player in computational genomics, has partnered with Genomenon, known for its industry-recognized Cancer Knowledgebase (CKB). This collaboration aims to enrich Intelliseq's flagship iFlow platform by incorporating a vast array of somatic variant data from Genomenon's CKB. This integration is set to empower clinical laboratories, researchers, and healthcare providers with precise and actionable insights for oncology.

The iFlow platform offers a cloud-based genomic analysis environment tailored for streamlining and scaling genomic diagnostics. It provides a unique environment that optimizes genome sequencing-based diagnostics, enhances treatment protocols, and supports preventive measure implementations. The platform’s modular architecture and diverse analytical pipelines encompass areas like rare disease diagnostics, tumor profiling, pharmacogenomics, and polygenic risk scoring, which allows labs to efficiently process and interpret vast genetic datasets.

Enhancements through Genomenon’s Expertise

The infusion of Genomenon’s CKB into the iFlow platform represents a leap forward in clinical interpretation capabilities regarding tumor variants. By utilizing precise and up-to-date somatic variant information, healthcare professionals will improve diagnostic accuracy and the personalization of treatment options for their patients. Intelliseq's commitment to accelerating the availability of digital tools for interpreting genetic variations is further underscored by this integration.

Klaudia Szklarczyk-Smolana, Co-Founder and CEO of Intelliseq, expressed enthusiasm about the partnership, stating, "Our goal is to enhance the clinical understanding of genetic variations. Integrating Genomenon’s expertly curated CKB empowers users with the most comprehensive somatic variant information available, facilitating more informed and confident clinical decisions in cancer treatment."

Genomenon’s Cancer Knowledgebase is internationally acclaimed for its detailed curation of somatic variants, which encapsulate the clinical relevance of each variant through evidence-based insights. This knowledgebase acts as a critical tool for clinical diagnostics, therapeutic selection, and further research in the cancer genomics field. By providing clear action points for understanding the genetic drivers of cancer, CKB empowers healthcare providers to harness genetic insights effectively.

Mike Klein, CEO of Genomenon, commented on the new partnership, highlighting the benefits of making CKB available through the innovative iFlow platform. "We are thrilled to partner with Intelliseq, aiding in expanding the reach of the Cancer Knowledgebase. This strategic integration allows laboratories and clinicians globally to utilize the prowess of genomics to elevate patient outcomes in cancer care."

A Commitment to Precision Medicine

This collaboration not only demonstrates both companies' dedication to improving precision medicine but also signifies a shared aspiration to deliver superior genomic data and digital solutions to the healthcare community worldwide. Intelliseq and Genomenon’s combined strengths could significantly impact how genetic information is interpreted in clinical settings, empowering healthcare professionals with better tools for managing cancer treatments.

About Intelliseq

Intelliseq excels in computational genomics, crafting advanced algorithms and models aimed at simplifying the analysis of large-scale human genetics data. Their iFlow platform enables users to design customizable genome analysis pipelines, thereby enhancing diagnostics and health monitoring efforts for laboratories and clinical programs.

About Genomenon

Genomenon is at the forefront of genomic intelligence, striving to transform patient care through in-depth analysis of the genetic underpinnings of diseases, particularly cancer. By leveraging AI technology grounded in a premier genomic dataset, Genomenon simplifies the complexities of genetic data into actionable insights, thus empowering healthcare clients in patient diagnosis and precision medicine development.

This partnership not only aligns both companies on a trajectory towards enhanced genetic analysis in oncology but sets a new benchmark for collaboration in the rapidly evolving field of genomic medicine.